35.36MMarket Cap-1833P/E (TTM)
1.060High1.020Low15.81KVolume1.060Open1.020Pre Close16.42KTurnover0.07%Turnover RatioLossP/E (Static)33.84MShares2.12052wk High-6.01P/B25.00MFloat Cap0.80852wk Low--Dividend TTM23.92MShs Float7.000Historical High--Div YieldTTM3.92%Amplitude0.808Historical Low1.038Avg Price1Lot Size
OKYO Pharma Stock Forum
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pai
OKYO Pharma Granted U.S. Patent Covering OK-101's Potential for Treating Symptoms of Dry Eye Disease
LONDON and NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated ...
Benzinga· 2 mins ago
No comment yet